Skip to content
EGFR-Sparing Anti-HER2 Drug Benefits Patients with Advanced HER2-Mutated Non-Small Cell Lung Cancer

EGFR-Sparing Anti-HER2 Drug Benefits Patients with Advanced HER2-Mutated Non-Small Cell Lung Cancer

Get the podcast

An interview with: John V Heymach MD PhD, Professor and Chair of Thoracic/Head and Neck Medical Oncology, Ruth Legett Jones Distinguished Chair, University of Texas MD Anderson Cancer Center, Houston

The Audio Journal of Oncology

An interview with:

John V Heymach MD PhD, Professor and Chair of Thoracic/Head and Neck Medical Oncology, Ruth Legett Jones Distinguished Chair, University of Texas MD Anderson Cancer Center, Houston TX

And with:

Jayesh Desai MD, Medical Oncologist, Associate Director Clinical Research, Peter MacCallum Cancer Centre, Melbourne, Australia, Co-Chair, AACR Clinical Committee.

CHICAGO, USA—A safer way of targeting tumors with mutated human epidermal growth factor receptor 2 (HER2) in patients with previously treated non-small cell lung cancer was discussed at the 2025 Annual Meeting of the American Association for Cancer Research, in Chicago.
Promising clinical benefits were reported from the Beamion LUNG-1 trial, in which patients were treated with the anti-HER2 tyrosine kinase inhibitor zongertinib that doesn’t affect the epidermal growth factor receptor (EGFR).

Audio Journal of Oncology correspondent Peter Goodwin met up with the study’s presenting author John V Heymach MD PhD, Chair of Thoracic/Head and Neck Medical Oncology, at the University of Texas MD Anderson Cancer Center in Houston, and with Jayesh Desai MD, Medical Oncologist at the Peter McCallum Cancer Centre in Melbourne Australia, Co-Chair of the AACR Clinical Committee, who moderated a press briefing held to discuss the findings of the Beamion LUNG-1 study.

Next in AACR 2025

All 14 interviews

Interview 11 of 14

Neoadjuvant PD-1 Blockade Enables Patients with Mismatch Repair Deficient Colorectal Cancers to Avoid Surgery

Neoadjuvant PD-1 Blockade Enables Patients with Mismatch Repair Deficient Colorectal Cancers to Avoid Surgery

An interview with: Andrea Cercek MD, Gastrointestinal Cancer Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York And: Ryan B Corcoran MD PhD, Director of the GI Cancer Program, Massac

3 May 2025
14 min

Related Episodes

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?

SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:

10 Nov 2026
10 min
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

4 Jun 2026
11 min
Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma

Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma

BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca

21 May 2026
11 min